Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer?

Journal of Clinical Oncology

Volumn 29, Issue 12, 2011, Pages 1504-1506

  Mackey, John R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; EXEMESTANE; TAMOXIFEN;

BREAST CANCER; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; GENETIC TRANSCRIPTION; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79955046633     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.3202     Document Type: Review

References (13)

1. Dowsett M, Cuzick J, Ingle J, et al: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509-518, 2010
2. Bartlett JMS, Brookes CL, Robson T, et al: Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: A prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 29:1531-1538, 2011
3. Jones SE, Seynaeve C, Hasenburg A, et al: Results of the first planned analysis of the TEAM (tamoxifen and exemestane adjuvant multinational) prospective randomized phase II trial in hormone sensitive postmenopausal early breast cancer. Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008 (abstr 15)
4. Sargent DJ, Conley BA, Allegra C, et al: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020-2027, 2005 (Pubitemid 46211382)
5. Dowsett M, Cuzick J, Wale C, et al: Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study. J Clin Oncol 23:7512-7517, 2005 (Pubitemid 46291814)
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
7. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002 (Pubitemid 34694019)
8. Dowsett M, Allred C, Knox J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059-1065, 2008
9. Viale G, Regan MM, Maiorano E, et al: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846-3852, 2007 (Pubitemid 47477259)
10. Hammond ME, Hayes DF, Wolff AC, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 6:195-197, 2010
11. Umemura S, Itoh J, Itoh H, et al: Immunohistochemical evaluation of hormone receptors in breast cancer: Which scoring system is suitable for highly sensitive procedures? Appl Immunohistochem Mol Morphol 12:8-13, 2004 (Pubitemid 38332312)
12. Baehner FL, Habel LA, Quesenberry CP, et al: Quantitative RT-PCR analysis of ER and PR by Oncotype DX™ indicates distinct and different associations with prognosis and prediction of tamoxifen benefit. Breast Cancer Res Treat 100:S20, 2006
13. Dowsett M, Cuzick J, Wale C, et al: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 28:1829-1834, 2010